Articles On Cardiex (ASX:CDX)

CardieX (CDX) and its manufacturing partner, Andon, submit its blood pressure and arterial health monitor, CONNEQT Pulse, to the US Food and Drug Administration (FDA) Subject to FDA clearance, Pulse will be the first arterial health monito...

Orthocell jumps 35% after signing global license deal Imricor in with Siemens deal on 3D imaging system CardieX submits “Pulse” application with US FDA  Orthocell (ASX:OCC) jumped by over 35% this morning after signing a 25-year exclusive...

CardieX is a step closer to launching its world first CONNEQT Pulse dual blood pressure monitor, after filing a clearance submission with the US FDA Australian medical technology companyn CardieX Limited (ASX:CDX), has, together with its ma...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The US FDA has classified CardieX’s (CDX) CONNEQT Companion app as a Medical Device Data System (MDDS) The app will work in line with the CONNEQT Pulse device, which is a dual blood pressure management system CardieX says the classificatio...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Supply chains are constrained globally as the world gets back on its feet This comes as inflation takes off, adding upward price pressures caused by scarcity of supply These conditions translate to major headwinds for contractors who agree...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

CardieX unveils the TicWatch GTH Pro made by global consumer electronics company Mobvoi using technology made by CDX’s subsidiary, ATCOR. The smartwatch uses ATCOR’s ‘Arty’ technology to measure central arterial waveforms and detect the ha...

The ASX200 has come to a jerky halt, closing more than 50 points or 0.7% higher. The market is down 5.6% over the last 52 weeks. The ASX Emerging Companies (XEC) index ended 0.6% better. The Four Horsemen of the Apocalypse are abroad on Mon...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

So basically, this is how I read it. Because of two really screwball takeover ideas involving the A2 Milk Co and AGL Energy —  two of the more screwball companies floating about on the benchmark index — the S&P/ASX200 is higher on Monda...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

CardieX’s (CDX) subsidiary teams up with Andiwn Scientific for a global clinical trial of ATCOR XCEL device and data management services ATCOR has entered a new global clinical trial services agreement with Andwin Scientific to support Syn...

Local stocks end up posting a solid session on Monday, following some steady gains on Wall Street on Friday night. Things looked shaky early, but the ASX 200 steadied in afternoon trade to finish around 0.5% higher. ASX 200 tech stocks rose...

ASX investors evidently shrugged off omicron fears in December, with the last month of the 2021 being the second best of the year. Ultimately, the market finished 2021 13% higher than it started. Patience pays off, unless you got in at the...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

Analysts have labelled CardieX and its blood pressure tech a Christmas buy for growth in 2022. A leading independent analyst has put a conservative buy price target – triple the current price – on Aussie medtech CardieX Limited (ASX:CDX) s...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

CardieX and Mobvoi are poised to release a world-first consumer smartwatch with proprietary heart-health features leveraging CardieX subsidiary ATCOR’s FDA-cleared SphygmoCor® technology. Australian medtech CardieX Limited (ASX:CDX) has an...

CardieX takes a step closer to world first wearable after signing manufacturing deal with Shenzhen-based Fenda Technology Co. Australian medtech, CardieX Limited (ASX:CDX) has entered into a manufacturing & development partnership with...

While Apple fanatics eagerly await its next smartwatch with a heart monitor, there are a couple of ASX stocks that are competing with them — and one might even be ahead. Apple’s (NDQ:AAPL) smartwatches first hit the market in 2015 and have...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

There’s no doubt there’s a building boom right now in the US, with the Biden administration investing big bucks to create and preserve more than 2 million sustainable homes as part of its Build Back Better Agenda. And while there’s volatili...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Stockhead’s Q-Wrapz video series features one-on-one interviews showcasing the latest quarterly results of emerging ASX companies. In this instalment, former CNBC, Sky News, and Bloomberg news anchor Oriel Morrison interviews Craig Cooper,...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

It’s been a big few weeks for CardieX (ASX:CDX) as the health technology company restructured itself into two divisions, worked to protect its intellectual property and announced a new strategic partnership. CardieX has five new products in...

Summary Little Green Pharma (ASX:LGP) boosts growth strategy, acquires production facility in Denmark Talga (ASX:TLG) signs supply deal with Nordic Battery maker FREYR Peppermint Innovation (ASX:PIL) closes strong on partnership with...

Summary The ASX 200 closed 1.48% higher at 7,342.20, recouping previous session losses. Ten of the 11 sectors ended in green, while the energy sector emerged as the top performer with 2.35% gain. Minding firm Pilbara Minerals was the...

Plenty of action on the biotech front today has provided ASX investors with some mouth-watering gains. Suda Pharma (ASX:SUD) led the pack, popping by as much as 44 per cent after announcing an oversubscribed $3.65 million capital raise. The...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Summary The benchmark index was up today, with most of the indices trading in the green zone. archTIS has secured a contract with an Australian national security agency to procure extra NC Protect software licences. Xref Limited repor...

Australian medtech CardieX has announced the launch of CONNEQT; a new consumer health division to focus on wearables and home health devices. CardieX (ASX: CDX), the Australian medical technology company, has announced that its subsidiary A...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Summary Health technology player CardieX Limited reported an impressive 29% growth in its sales during Q2 FY2021. XCEL and Oscar 2 devices reported robust sales numbers despite the COVID-19 pandemic. The Company is expected to launch...

The Cardiex Ltd (ASX: CDX) share price is up 3.9% to 5.3 cents in afternoon trading after the company released a positive update on its half year sales. The rise comes as the wider All Ordinaries Index (ASX: XAO) is slipping, down 0.2% to...

The Cardiex Ltd (ASX: CDX) share price was rising today as the company announced it had received a new blood pressure patent. The Cardiex share price closed today’s trading 6.12% higher at 5.2 cents. What Cardiex does Cardiex is a global h...

A quick wrap of the ASX’s key winners and losers on Wednesday, September 16. Data is taken after the market closes at 4pm AEST. Stocks highlighted in yellow made potentially market-moving announcements during the day. WINNERS TICKE...

Special Report: CardieX has inked one of its most significant deals to date, securing a partnership with one of China’s largest electronic medical device manufacturers and opening the doors to a US$509 billion market opportunity. CardieX (A...

Seasoned financial advisor, investment manager and corporate director Dr Nigel Finch is back in the radio booth for another instalment of The StockDoc Podcast. This week, the good doctor sits down with Craig Cooper, CEO & managing direc...